Terminated PHASE1 INTERVENTIONAL 7-arm NCT00818259

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)

A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy

Sponsor: Merck Sharp & Dohme LLC

Conditions Chemotherapy-Induced Nausea and Vomiting

Interventions Comparator: ondansetron Dexamethasone Experimental: aprepitant Experimental: fosaprepitant Ondansetron

Updated 13 times since 2017 Last updated: Aug 27, 2018 Started: Feb 5, 2009 Primary completion: Jan 20, 2014 Completion: Jan 20, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated early prior to completing targeted enrollment of participants \<6 months of age due to recruitment challenges.

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

This PHASE1 trial investigates Chemotherapy-Induced Nausea and Vomiting and is currently terminated or withdrawn. Merck Sharp & Dohme LLC leads this study, which shows 13 recorded versions since 2009 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

13 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jun 2022 — Jul 2024 [monthly]

Terminated PHASE1
Dec 2021 — Jun 2022 [monthly]

Terminated PHASE1
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE1

▶ Show 8 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE1
Oct 2018 — Nov 2020 [monthly]

Terminated PHASE1
Jun 2018 — Oct 2018 [monthly]

Terminated PHASE1
May 2018 — Jun 2018 [monthly]

Terminated PHASE1
Aug 2017 — May 2018 [monthly]

Terminated PHASE1
Jul 2017 — Aug 2017 [monthly]

Terminated PHASE1
Feb 2017 — Jul 2017 [monthly]

Terminated PHASE1
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.